Skip to main content
Clinical Trials/NCT05271838
NCT05271838
Unknown
Not Applicable

Nutritional Therapy for Patients With Acute Severe Ulcerative Colitis (ASUC) Treated With High-dose Steroids - a Special Focus on Protein and Magnesium.

University of Aarhus1 site in 1 country36 target enrollmentFebruary 8, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Inflammatory Bowel Diseases
Sponsor
University of Aarhus
Enrollment
36
Locations
1
Primary Endpoint
24 hour urine carbamide (mmol/d)
Last Updated
4 years ago

Overview

Brief Summary

The aim of the study is to improve the quality of nutritional therapy for patients admitted with Acute Severe Ulcerative Colitis (ASUC) treated with high-dose steroids. This study consists of two randomized interventions and one observational part regarding protein, magnesium, and metabolic stress. First an interventional part aims to explore the effect of a high-protein diet during and after admission on different parameters regarding protein turnover.Second the study aims to explore the degree of magnesium depletion in ASUC. In case of magnesium depletion, the study aims to investigate whether oral magnesium supplementation can regain body stores of magnesium. Last the study aims to observe the degree of metabolic stress, including, the degree of insulin resistance, in ASUC during admission and under treatment with high-dose steroids compared to three weeks after discharge.

Detailed Description

Patients with Acute Severe Ulcerative Colitis (ASUC) may have an altered protein turnover due to inflammation, reduced dietary intake and/or accelerated protein loss. Despite this the level of dietary protein needed to maintain nitrogen balance has never been described in patients with ASUC. Clinical symptoms of ASUC include frequent and bloody diarrhea which alone or simultaneous with a risk of reduced dietary intake and weightloss can lead to magnesium depletion. Magnesium depletion can cause severe symptoms including cardiac arrhythmia and neuromuscular dysfunction which might worsen the disease further. The prevalence of magnesium depletion in ASUC has never been described and furthermore it is not known whether oral supplementation are able to reverse the condition in patients with ASUC.

Registry
clinicaltrials.gov
Start Date
February 8, 2022
End Date
July 1, 2022
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christian Hvas

Associate professor, MD PhD

University of Aarhus

Eligibility Criteria

Inclusion Criteria

  • Age 18 years or older
  • Cognizant
  • Must speak or read Danish or participate in relevant communication in interpreting or translating the study material.
  • Diagnosed with Acute Severe Ulcerative Colitis (ASUC) (documented in the patient journal)
  • Admitted at "Lever-, Mave-, og Tarmsygdomme/ LMT" at Aarhus University Hospital and in medical treatment with high-dose intravenous steroid (Solumedrol 40 mg x 2 daily)

Exclusion Criteria

  • Pregnant and/or lactating women
  • Plasma creatinine \> 200 µmol/L (protein intervention only)
  • Patients receiving tube- or parenteral feeding (protein intervention only)
  • Receiving any kind of magnesium supplementation 6 months prior to inclusion (magnesium intervention only)
  • Diagnosed with Type 1 or Type 2 Diabetes Mellitus (observational part only)

Outcomes

Primary Outcomes

24 hour urine carbamide (mmol/d)

Time Frame: 5 days

Change in 24 hour urine carbamide (mmol/d) from baseline (day 0) to first follow-up (day 5)

Secondary Outcomes

  • plasma carbamide (mmol/l)(0, follow-up 1 (day 5) and week 4)
  • 24 hour urine carbamide (mmol/d)(4 weeks)
  • 24 hour urine magnesium (mmol/d)(3 weeks)
  • Fat free mass (FFM) (kg)(4 weeks)
  • Fasting blood glucose (mmol/l)(4 weeks)
  • Quality of life (QOL) questionaire (Hjortswang index)(3 weeks)
  • plasma insulin (pmol/l)(4 weeks)
  • Magnesium retention %(3 weeks)
  • Resting Energy Expenditure (REE)(4 weeks)
  • plasma magnesium (mmol/l)(4 weeks)
  • plasma c-peptide (pmol/l)(4 weeks)
  • Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)-score(4 weeks)
  • 24 hour urine creatinine (mmol/d)(0, follow up 1 (day 5) and week 4)
  • Quality of life (QOL) questionaire (SIBDQ)(3 weeks)
  • Body weight (kg)(4 weeks)
  • plasma albumin (g/L)(4 weeks)
  • Creatinine-clearance (mL/min)(0, follow-up 1 (day 5) and week 4)

Study Sites (1)

Loading locations...

Similar Trials